Serum cytokines profile changes in amyotrophic lateral sclerosis

Chun-Zuan Xu; Xiao Huan; Su-Shan Luo; Hua-Hua Zhong; Chong-Bo Zhao; Yan Chen; Zhang-Yu Zou; Sheng Chen

doi:10.1016/j.heliyon.2024.e28553

Serum cytokines profile changes in amyotrophic lateral sclerosis

Heliyon. 2024 Mar 27;10(7):e28553. doi: 10.1016/j.heliyon.2024.e28553. eCollection 2024 Apr 15.

Authors

Chun-Zuan Xu^{1

2}, Xiao Huan^{3

4}, Su-Shan Luo^{3

4}, Hua-Hua Zhong^{3

4}, Chong-Bo Zhao^{3

4}, Yan Chen^{3

4}, Zhang-Yu Zou^{1

2}, Sheng Chen^{1

2}

Affiliations

¹ Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
² Institute of Clinical Neurology, Fujian Medical University, Fuzhou, China.
³ Department of Neurology, Fudan University Huashan Hospital, Shanghai, China.
⁴ National Center for Neurological Disorders, Shanghai, China.

Abstract

Background: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder, characterized by progressive limb weakness, dysphagia, dysphonia, and respiratory failure due to degeneration of upper and lower motor neurons. The pathogenesis of ALS is still unclear. Neuroinflammation has been found to be involved in its development and progression. Cytokines play a significant role in the inflammatory process. This study aims to identify novel biomarkers that may assist in the diagnosis of ALS.

Methods: In Fujian Medical University Union Hospital and Huashan Hospital Fudan University, two independent centers, we prospectively recruited 50 ALS patients, and 41 healthy controls (25 ALS and 26 controls in the first stage and 25 ALS and 15 controls in the validation stage). An 18-plex Luminex kit was used to screen the serum cytokines levels in the first stage. Commercial ELISA kits were used to measure the levels of target cytokines in the validation stage. A single-molecule array HD-X platform was applied to assess the levels of serum neurofilament light chain (NFL).

Results: The levels of serum IL-18 were markedly increased in patients with ALS in the first stage (p = 0.016). The ROC curve showed an area under the curve at 0.695 (95% CI 0.50-0.84) in distinguishing ALS patients from healthy controls. The IL-21 was decreased in elderly patients when grouped by 55 years old (the medium age). Furthermore, the IL-5, IL-13, IL-18, and NFL had a positive relationship with the disease progression of ALS. We also found that serum IL-18 was markedly increased in ALS patients in the validation stage (167.67 [148.25-175.59] vs 116.44 [102.43-122.19]pg/ml, p < 0.0015).

Conclusion: In this study, we identified systemic cytokine profile changes in the serum of ALS patients, especially the elevated IL-18, as well as the decreased IL-21 in elder patients. These changes in serum cytokine profiles may shed new light on an in-depth understanding of the immunopathogenic characteristics of ALS.

Keywords: Amyotrophic lateral sclerosis; Biomarker; Cytokine; IL-18; IL-21; Neurofilament light chain.